GlassScriptPhysician profile
Ivey Grace Appel Sharp
NPI 1609520279
$1,225.80
in general payments reported to CMS, 2019-2025
26 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $527 · 2023: $179 · 2024: $283 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $339.56 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $178.15 | 2023-2025 | Gemtesa |
| Pfizer INC. | $61.75 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.74 | 2022-2023 | |
| Amgen INC. | $40.94 | 2022 | |
| Novo Nordisk INC | $40.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.52 | 2022 | |
| Amarin Pharma, INC. | $38.66 | 2022 | |
| Mayne Pharma Commercial LLC | $36.97 | 2024-2025 | |
| Sage Therapeutics, LLC | $35.55 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2022 | |
| Optinose US, INC. | $34.38 | 2022 | |
| Coopersurgical, INC. | $23.75 | 2024 | Paragard T 380a |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.05 | 2022 | |
| Therapeuticsmd, INC. | $18.98 | 2022 | |
| Glaxosmithkline, LLC. | $18.81 | 2023 | Shingrix, Bexsero, Pediarix |
| Exeltis, USA INC. | $18.70 | 2023 | Slynd |
| Convatec INC. | $18.24 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.14 | 2022 | |
| Scynexis, INC. | $17.28 | 2022 | |
| Evofem Biosciences, INC. | $16.35 | 2023 | Phexxi |
| Janssen Pharmaceuticals, INC | $16.00 | 2022 | |
| Exact Sciences Corporation | $14.68 | 2024 | Cologuard Collection Kit |
| Organon LLC | $9.81 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivey Grace Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.